Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Tirzepatide improves glycemic control and weight loss in type 2 diabetes
Última actualización 4 de julio de 2026
Key finding
LS mean reductions in HbA1c were significantly greater in patients with a higher baseline HbA1c.
The study analyzed the efficacy of tirzepatide in patients with type 2 diabetes, showing significant reductions in HbA1c, body weight, and fasting serum glucose.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study analyzed the efficacy of tirzepatide in patients with type 2 diabetes, showing significant reductions in HbA1c, body weight, and fasting serum glucose.
Clinical relevance
These findings are clinically significant as they suggest that tirzepatide may offer a more effective treatment alternative for managing type 2 diabetes, potentially leading to better patient outcomes. With obesity being a common issue among diabetes patients, the weight loss associated with tirzepatide could also help improve overall health and reduce diabetes-related complications.
Keep in mind
Effectiveness of tirzepatide doses was unclear for gastrointestinal adverse events. Hypoglycemia outcomes were evaluated but not specified in results. Study results may not be generalizable to all populations with type 2 diabetes.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Yan B, Song L, Jiani T, Liying D, Linong J. Post Hoc Analysis of SURPASS-AP-Combo: Efficacy of Tirzepatide in Patients with Type 2 Diabetes. Diabetes Therapy. 2024;15(5):1125-1137. doi:10.1007/s13300-024-01561-2
Efectos Principales
All tirzepatide doses reduced HbA1c by -2.52% (p=0.001).
All tirzepatide doses reduced body weight by -5.83 kg (p=0.01).
All tirzepatide doses reduced fasting serum glucose by -15 mg/dL (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and Body weight, Daily glucose average, Gastrointestinal disorders incidence, and 3 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- Body weight
- Daily glucose average
- Gastrointestinal disorders incidence
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
362
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Fasting Glucose
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Tirzepatide → Gastrointestinal disorders incidence
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Tirzepatide significantly reduced HbA1c levels by -2.52%.
- Tirzepatide led to a weight loss of -5.83 kg.
- Fasting serum glucose decreased by -15 mg/dL with tirzepatide.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients seeking alternatives to insulin therapy.
Tener en Cuenta
- Further studies are needed to evaluate long-term safety and efficacy.
- The study's population may not represent all demographics of diabetes patients.
- Gastrointestinal adverse events and hypoglycemia were not fully detailed.
Entre Líneas
- Effectiveness of tirzepatide doses was unclear for gastrointestinal adverse events.
- Hypoglycemia outcomes were evaluated but not specified in results.
- Study results may not be generalizable to all populations with type 2 diabetes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 9 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 84
- Strong
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 8 studies
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
9 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
9 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
8 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
9 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
8 results
All studies on Tirzepatide
Intervention: Tirzepatide
9 results
All studies measuring HbA1c
Outcome: HbA1c
9 results
All studies measuring Body weight
Outcome: Body weight
8 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 84.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 27 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Serum Glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Hypoglycemia events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetesMetformin and glimepiride with basal insulin lowered HbA1c the most
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.